Table 3.

Binuclear metal complexes with SBs.

Structure	Compound	Antimicrobial and Antioxidant Activities	IC50	Ref
	CuL1 (27)	-	IC50 = 9.48 ± 0.24 µM (MCF-7) IC50 = 10.15 ± 0.6 µM (A549)	Keypour et al., 2021 [89]
	NiL1 (28)	-	IC50 = 12.16 ± 0.79 µM (MCF-7) IC50 = 13.63 ± 0.91 µM (A549)	Keypour et al., 2021 [89]
	Bi2(HL)2(NO3)4 (29)	-	IC50 = 3.93 × 10−4 mol/L (S. pombe)	Lei et al., 2022 [90]
	(30)	MIC = 2 μg/mL and 1.38 μM (S. aureus Newman)	IC50 = 0.23 ± 0.09 μM (SNU-16)	Li et al., 2022 [91]
	Z1 (31)	IZD = 16 mm (S. aureus PTCC1431) IZD = 15 mm (B. cereus PTCC1015)	-	Kargar et al., 2022 [85]
	Z2 (32)	IZD = 11 mm (S. aureus PTCC1431) IZD = 11 mm (B. cereus PTCC1015)	-	Kargar et al., 2022 [85]
	33	CFU/mL = 2.2 × 105 (E. coli ATCC 25922); Antibacterial rate = 85% CFU/mL = 6.0 × 105 (S. aureus ATCC 6538); Antibacterial rate = 88%	IC50 = 103 μM (MCF-7)	Goudarzi et al., 2022 [92]
	34	CFU/mL = 1.8 × 105 (E. coli ATCC 25922); Antibacterial rate = 85% CFU/mL = 5.1 × 105 (S. aureus ATCC 6538); Antibacterial rate = 66%	IC50 = 89 μM (MCF-7)	Goudarzi et al., 2022 [92]
	Cu-Gd complex (35)	-	IC50 = 36.09 ± 4.11 µM (MCF-7) IC50 = 15.66 ± 2.92 (HeLa) IC50 = 20.23 ± 4.77 (LNCaP) IC50 = 96.62 ± 3.11 (normal fibroblasts)	Keshavarzian et al., 2022 [93]
	Cu(II) complex (36)	Scavenging inhibition (%) = 40.92% (DPPH) scavenging inhibition (%) = 87.12% (ABTS)	IC50 = 31.88 μM (Caco-2) IC50 = 285 μM (L-929)	Savcı et al., 2022 [94]
	Pd(II) complex (37)	Scavenging inhibition (%) = 80.48% (DPPH) scavenging inhibition (%) = 43.15% (ABTS)	IC50 = 25.35 μM (Caco-2) IC50 = 114.28 μM (L-929)	Savcı et al., 2022 [94]
	CuII2L(μ1,1-NO3)(μ-OH)(NO3)(H2O) (38)	-	IC50 = 49.92 ± 4.90 µmol/L (MCF-7) IC50 = 21.53 ± 2.72 µmol/L (HeLa) IC50 = 29.32 ± 5.42 µmol/L (LNCaP) IC50 = 73.03 ± 4.16 µmol/L (Normal Skin Fibroblasts)	Jahromi et al., 2022 [95]